Precigen (NASDAQ:PGEN) Shares Gap Up on Analyst Upgrade

Precigen, Inc. (NASDAQ:PGEN) gapped up prior to trading on Thursday after Citizens Jmp raised their price target on the stock from $8.00 to $9.00. The stock had previously closed at $3.10, but opened at $4.07. Citizens Jmp currently has a market outperform rating on the stock. Precigen shares last traded at $3.9670, with a volume of 10,133,553 shares traded.

Several other research analysts have also recently issued reports on PGEN. Weiss Ratings reissued a “sell (d-)” rating on shares of Precigen in a research note on Thursday, January 22nd. HC Wainwright raised their target price on Precigen from $9.00 to $10.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Zacks Research upgraded shares of Precigen from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Precigen currently has an average rating of “Hold” and an average price target of $9.50.

Trending Headlines about Precigen

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: PAPZIMEOS commercial momentum — Precigen reports accelerating U.S. launch demand, broad payer coverage and expects Q1 revenue to exceed $18M (company guidance), supporting a rising near‑term revenue run‑rate. Precigen expects Q1 revenue to exceed $18M
• Positive Sentiment: CMS coding and access tailwind — A permanent J‑code (J3404) for PAPZIMEOS effective April 1 will streamline claims and likely improve reimbursement/uptake. This is a direct commercial enabler for sustained sales growth. Precigen Reports Full Year 2025 Financial Results and Business Updates
• Positive Sentiment: Analyst upgrades and higher price targets — Multiple firms raised targets/ratings (Citizens JMP to $9, HC Wainwright to $10), signaling stronger sell‑side conviction around commercial upside and valuation re‑rating. Benzinga price target coverage
• Positive Sentiment: Cash runway and breakeven plan — Management reports ~$100.4M in cash and expects operations to reach cash‑flow breakeven in 2026, reducing near‑term financing risk. Precigen Reports Full Year 2025 Financial Results and Business Updates
• Neutral Sentiment: Analyst valuation note — A recent Seeking Alpha piece models scenario‑weighted fair value around $6.13 (base case ~$7.01), highlighting upside versus current levels but dependent on sustained commercial execution. Precigen: The Best Potential Blockbuster You’ve Never Heard Of
• Neutral Sentiment: Regulatory/clinical updates — EMA validated an MAA for PAPZIMEOS and an open‑label redosing study was initiated; these are medium‑term positives but will take time to materially affect revenue. Precigen Reports Full Year 2025 Financial Results and Business Updates
• Negative Sentiment: Mixed Q4 results — EPS slightly beat expectations (reported roughly breakeven per share vs. a larger expected loss), but product/total revenue of ~$4.57M missed consensus (~$8.3M), showing launch sales still ramping and generating near‑term volatility in reported numbers. PGEN Q4 earnings summary
• Negative Sentiment: Short‑term execution risk — Revenue is still concentrated on an early launch with payer rollout timing and demand variability; missed revenue estimates underscore execution risk that could pressure the stock if quarterly cadence disappoints. Zacks: Precigen Reports Q4 Loss, Lags Revenue Estimates

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Patient Capital Management LLC grew its stake in Precigen by 62.6% during the 3rd quarter. Patient Capital Management LLC now owns 26,460,848 shares of the biotechnology company’s stock valued at $87,056,000 after acquiring an additional 10,192,107 shares in the last quarter. State Street Corp boosted its holdings in shares of Precigen by 141.1% during the fourth quarter. State Street Corp now owns 10,824,860 shares of the biotechnology company’s stock worth $45,248,000 after purchasing an additional 6,335,033 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Precigen by 15.9% during the fourth quarter. Geode Capital Management LLC now owns 4,462,078 shares of the biotechnology company’s stock worth $18,653,000 after purchasing an additional 613,340 shares during the period. Occam Crest Management LP grew its position in Precigen by 29.6% during the fourth quarter. Occam Crest Management LP now owns 3,501,739 shares of the biotechnology company’s stock valued at $14,637,000 after purchasing an additional 799,339 shares in the last quarter. Finally, SymBiosis Capital Partners LLC acquired a new position in Precigen in the 4th quarter valued at approximately $12,540,000. 33.51% of the stock is owned by institutional investors and hedge funds.

Precigen Trading Up 25.3%

The company has a debt-to-equity ratio of 2.22, a quick ratio of 3.95 and a current ratio of 4.04. The stock has a market cap of $1.37 billion, a price-to-earnings ratio of -2.90 and a beta of 1.10. The company’s 50 day simple moving average is $4.10 and its two-hundred day simple moving average is $3.98.

Precigen (NASDAQ:PGEN) last issued its earnings results on Wednesday, March 25th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.09. Precigen had a negative net margin of 2,588.21% and a negative return on equity of 2,313.82%. The company had revenue of $4.57 million during the quarter, compared to analyst estimates of $8.29 million. Research analysts expect that Precigen, Inc. will post -0.32 EPS for the current fiscal year.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.